An FDA advisory committee is meeting on Thursday to discuss whether flibanserin — a drug sometimes nicknamed ‘women’s viagra’ — should be approved to treat low libido in women.
If approved, the drug would be marketed as treatment for hypoactive sexual desire disorder, which is said to cause a low sex drive in women. Some supporters argue the drug has a role in gender equality and that women do not have the same resources as men to deal with various degrees of sexual dysfunction.
The drug, owned by Sprout Pharmaceuticals, has been rejected by the agency two times already. The argument being that its benefit is not notable enough to outweigh its side effects which can include dizziness and nausea.
Other pharmaceutical companies including Pfizer and Procter & Gamble have made attempts at drugs to treat lack of libido among women. So far they have not been successful.
The FDA’s Thursday meeting on flibanserin is open to the public.
More Must-Reads from TIME
- Why Trump’s Message Worked on Latino Men
- What Trump’s Win Could Mean for Housing
- The 100 Must-Read Books of 2024
- Sleep Doctors Share the 1 Tip That’s Changed Their Lives
- Column: Let’s Bring Back Romance
- What It’s Like to Have Long COVID As a Kid
- FX’s Say Nothing Is the Must-Watch Political Thriller of 2024
- Merle Bombardieri Is Helping People Make the Baby Decision
Contact us at letters@time.com